key: cord-0924411-sy9hpgwn
authors: Piñana, José Luis; Garcia-Sanz, Ramon; Martino, Rodrigo; Garcia-Roa, María; Martin-Martin, Gabriel Andrés; Risco-Gálvez, Irene; Tormo, Mar; Martinez-Barranco, Pilar; Marcos-Corrales, Sara; Calabuig, Marisa; Conesa, Venancio; Teruel, Anabel; Ruiz-Pérez, Sara; Solano, Carlos; Navarro, David; Cedillo, Ángel; Sureda, Anna
title: Booster effect after SARS-CoV-2 vaccination in hematological immunocompromised patients with prior COVID-19
date: 2021-12-16
journal: Blood Adv
DOI: 10.1182/bloodadvances.2021006326
sha: 11d87d65e303ab258cd210648eb5c6e582d15ef7
doc_id: 924411
cord_uid: sy9hpgwn

nan

Patients with hematological malignancies have been excluded from the new zoonotic coronavirus (SARS-CoV-2) vaccine trials 1,2 despite being at higher risk of SARS-CoV-2 disease (COVID-19)-related mortality [3] [4] [5] . However, most health authorities worldwide have designated these patients as a priority for COVID-19 vaccination [6] [7] [8] [9] [10] [11] [12] In order to provide some rational for these two pressing questions, we report a casecontrol analysis of the probabilities of displaying detectable SARS-CoV-2-reactive IgG antibodies (SCoV2-R-A) at 3 weeks after full vaccination schedule in a large series of hematological patients with prior history of SARS-CoV-2 infection (as defined by either molecular or serological tests for SARS-CoV-2) before the first vaccine dose. The SCoV2-R-A detection rate in this cohort was compared to that observed in a control cohort of patients without evidence of prior SARS-CoV-2 infection at the time of vaccination. The later included hematological malignancy patients with either no prior polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection and negative SCoV2-R-A serology testing within 2 weeks of the first vaccine dose. The next step was to exclude patients with hematological malignancies and/or procedures not represented in the study group. The presence of SCoV2-R-A was determined at each center using serological ELISA or chemiluminescence immunoassays following the manufacturers' instructions according to their availability at the microbiology services of each participating center. The techniques used are shown in the supplementary table S1. For the study purpose, we defined antibody detection or seropositivity when SCoV2-R-A were detected at any level above the lower limit level of detection for each of the tests used. The primary endpoints were to compare the rate of post-vaccination seropositivity for SCoV2-R-A between cohorts, to identify the main factors associated with seropositivity and to describe the characteristics of SCoV2-R-A detection in those with prior SARS-CoV-2 infection as a model of a somewhat more natural immunological booster.

Overall, this series included 461 hematological patients. The first cohort included 99 patients with prior SARS-CoV-2 infection whereas the control cohort included 362 patients without prior COVID-19 history and negative SCoV2-R-A serological test before the first vaccine dose. Clinical characteristics of both cohorts are detailed in Table 1 . Eighty-two out of 99 patients (82%) had prior PCR-confirmed COVID-19, Table 2 . Multivariate analysis confirmed that prior COVID-19 was the main factor associated with detectable SCoV2-R-A after vaccination (OR 4.04, p= 0.001), whereas diagnosis of B-cell non-Hodgkin's lymphoma (NHL), corticosteroids and lymphopenia <1x10e9/mL at vaccination were associated with lower rates of SCoV2-R-A detection. Prior exposure to anti-CD20 therapy was also significantly associated with a lower response rate when we remove B-cell NHL from the multivariate analysis model (see foot note in table 2).

Our findings indicate that patients with hematological malignancies with a prior history of SARS-CoV-2 infection achieve high SCoV2-R-A detection rates (93%), similar to that reported in clinical trials in healthy population with mRNA vaccines 1-2 . The most important limitation of this study is the use of several serological tests which may differ in the detection range, sensitivity, and specificity. Thus, further confirmation of our findings using WHO standardized tests is a priority for future research. Our finding indicates that these patients may not require an immediate SARS-CoV-2 vaccine booster dose irrespective of the current or past treatments, type and status disease or the absolute lymphocyte count at the time of vaccination. Furthermore, SARS-CoV-2 full dose vaccination was able to reach seroconversion in 83% of patients with prior negative SCoV2-R-A despite prior COVID-19. This data suggests that a booster dose in these highly immunosuppressed patients could likely elicit a humoral response similar to that observed in the healthy population and likely higher than prior experiences with mRNA SARS-CoV-2 vaccine booster doses in solid organ transplant recipients, where the additional dose increased the seroconversion rate from 40% to 68% 14, 15 . Although SARS-CoV-2 antibody detection rate in hematological patients with prior SARS-CoV-2 infection looks similar to the general population and an up-front third dose could be questionable, it remains to be determine if the duration of such a response is similar to the general population's since immunocompromised patients may have more rapidly decreasing antibody titers, especially those who have undergone allogeneic stem cell transplantation or those in active treatment. If such a serological behavior is confirmed a third dose could be advisable in this scenario. In line with early studies, we report that B-cell NHL patients 6, 11 (or those treated with anti-CD20 monoclonal antibodies), lymphopenia < 1x10e9/mL 8 and corticosteroid therapy 16 were associated with lower probabilities of mounting SCoV2-R-A. The significant effect of anti-CD20 monoclonal antibody therapy, after removing B-cell NHL patients from the multivariate analysis, could be linked to chronic lymphocytic leukemia (CLL). However, we were not able to properly analyze the effect of anti-CD20 monoclonal antibody therapy in CLL patients due to the limited number of such patients. Until more disease-specific data are available, these factors could be used to guide physicians in patient counseling with respect to a third vaccine dose. However, we think that a third dose should be given in the context of prospective randomized clinical trials in order to overcome the lack of such evidence in these highly immunosuppressed patients. Finally, the limitation of this study included the use of different serological tests in each center which results were not harmonized, the lack of neutralizing antibody testing and the lack of SCoV2-R-A quantification in a significant number of cases. In contrast, the multicenter design along with the large number of patients included should be regarded as strengths.

For data sharing, contact the corresponding author: jlpinana@gmail.com.

Translational Research. We thank the Spanish Society of Hematology (SEHH) for its support on the study diffusion. We sincerely want to thanks the invaluable aid of ≠We included 90 patients with B-cell NHL, of whom 69 (77%) received antiCD20 therapy prior to vaccination (including 11 vaccinated after ASCT), whereas 21 (23%) were vaccinated after allogeneic stem cell transplantation. Thus, a high collinearity (100%) was observed between B-cell NHL not allografted and prior antiCD20 therapy. In MVA, if we include Rituxan along with the base line disease, the only significant variable associated with a lower response rate was B-cell NHL. In contrast, after removing base line disease and including prior antiCD20 therapy we observed a significant association with lower response rate. The rest of significant variable remain unchanged.

® Regarding CLL, we included 48 patients. Seventeen (35%) were in the watch and wait approach whereas 5 (10%) were more than one year after allo-SCT and 9 (19%) were in complete remission for more than 1 year before vaccination without active therapy. Finally, the remaining 17 patients with CLL were on treatment at the time of vaccination. Four of them received Bruton's TKI (n=2) or venetoclax (n=2) both in combination with antiCD20 therapy, whereas 13 patients were on Bruton's TKI monotherapy. Thus only 13 out of 48 patients with CLL (27%) received Rituxan prior to vaccination, and 9 of them more than one year before vaccination. This highly heterogenous population of CLL patients may have precluded our ability to identify poor responders.

Instituto de Investigación Sanitaria Hospital Clínico Universitario de

Hematology Division, Hospital General Universitari d'Elx

Microbiology department

Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)

C4591001 Clinical Trial Group Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

for the COVE Study Group*. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)

Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

of the GELLC (Grupo Español de Leucemia Linfática Crónica). Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Safety and Tolerability of SARS-CoV-2 Emergency-Use Authorized Vaccines Allogeneic Hematopoietic Stem Cell Transplant Recipients. Transplant Cell Ther

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2